Camargo Pharmaceutical Services is an experienced global strategist providing comprehensive drug development services specialized for the 505(b)(2) new drug application approval pathway and analogous European processes.
“At this exciting and critical stage in the development of C-103, our leadership team and Advisory Board believe it is prudent to engage Camargo’s guidance and expertise,” the company said.
C-103 is intended to maintain the efficacy of orlistat while minimizing its socially unacceptable side effects.
In an update for shareholders, the company said it continues to make good progress with its product pipeline.
Story by ProactiveInvestors